Integra LifeSciences (NASDAQ:IART) Updates FY 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share guidance of 2.190-2.290 for the period, compared to the consensus earnings per share estimate of 2.460. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its Q2 2025 guidance to 0.400-0.450 EPS.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on IART. JPMorgan Chase & Co. dropped their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research note on Tuesday. Wells Fargo & Company decreased their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a report on Tuesday. Truist Financial lowered their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Finally, Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $19.88.

Integra LifeSciences Stock Performance

IART stock traded down $0.02 during mid-day trading on Wednesday, hitting $12.73. 1,486,262 shares of the company were exchanged, compared to its average volume of 1,042,489. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $983.39 million, a PE ratio of -141.43, a price-to-earnings-growth ratio of 0.73 and a beta of 1.27. The business has a 50 day simple moving average of $19.31 and a 200-day simple moving average of $21.96. Integra LifeSciences has a 1-year low of $11.60 and a 1-year high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The business had revenue of $382.65 million for the quarter, compared to the consensus estimate of $381.17 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company's revenue was up 3.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.55 earnings per share. On average, equities analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.